Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.74 |
| ▸ | GSK3B | P49841 | 5/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.74 |
| ▸ | CLK2 | P49760 | 4/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.74 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.74 |
| ▸ | CDK8 | P49336 | 3/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.74 |
| ▸ | PIM1 | P11309 | 2/20 | 0.74 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.74 |
| ▸ | CDK9 | P50750 | 2/20 | 0.74 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.74 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.74 |
| ▸ | MET | P08581 | 1/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802149 | 0.90 | CDK5 (0.68) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3799598 | 0.90 | CDK5 (0.68) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3798638 | 0.88 | GSK3A (0.64) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3805910 | 0.84 | CDK5 (0.83) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3797427 | 0.82 | MEN1 (0.63) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3800165 | 0.82 | GSK3A (0.61) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL31061009 | 0.82 | GSK3B (1.00) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL3795310 | 0.82 | GSK3B (1.00) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL4562332 | 0.82 | GSK3A (0.56) | GSK3AGSK3BCDK5PRKD3MAP4K4 | |
| SCHEMBL14517926 | 0.81 | PRKD3 (0.75) | GSK3AGSK3BCDK5PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8642598-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2091943-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2013-11-20 | — | — | EP | disclosed |
| EP-2535336-A1 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | Abbott GmbH & Co. KG (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG. (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-2091943-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008046919-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | GSK3A 2/4885GSK3B 1/4885CDK5 152/4885 |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | GSK3A 2/4885GSK3B 1/4885CDK5 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.